Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
WST Quote, Financials, Valuation and Earnings
Last price:
$274.67
Seasonality move
:
4.65%
Day range:
$272.83 - $277.50
52-week range:
$187.43 - $348.90
Dividend yield:
0.31%
P/E ratio:
40.63x
P/S ratio:
6.62x
P/B ratio:
6.47x
Volume:
344.5K
Avg. volume:
691.8K
1-year change:
-17.73%
Market cap:
$19.7B
Revenue:
$2.9B
EPS (TTM):
$6.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$760M | $1.65 | 6.25% | 3.35% | $345.71 |
|
BDX
Becton, Dickinson & Co.
|
$5.5B | $3.37 | -0.31% | 169.42% | $204.83 |
|
BSX
Boston Scientific Corp.
|
$5.2B | $0.80 | 15.97% | 105.65% | $125.86 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.6B | $2.12 | 12.86% | 19.35% | $599.60 |
|
MASI
Masimo Corp.
|
$398.2M | $1.43 | -32.15% | 565.51% | $183.75 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.77 | 8.96% | 16.17% | $291.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$274.30 | $345.71 | $19.7B | 40.63x | $0.22 | 0.31% | 6.62x |
|
BDX
Becton, Dickinson & Co.
|
$196.33 | $204.83 | $56B | 33.68x | $1.05 | 2.12% | 2.59x |
|
BSX
Boston Scientific Corp.
|
$96.06 | $125.86 | $142.4B | 51.38x | $0.00 | 0% | 7.41x |
|
ISRG
Intuitive Surgical, Inc.
|
$577.81 | $599.60 | $204.8B | 76.48x | $0.00 | 0% | 21.86x |
|
MASI
Masimo Corp.
|
$132.76 | $183.75 | $7.1B | 116.80x | $0.00 | 0% | 4.20x |
|
RMD
ResMed, Inc.
|
$244.76 | $291.80 | $35.7B | 25.05x | $0.60 | 0.92% | 6.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
9.03% | 1.397 | 1.61% | 2.02x |
|
BDX
Becton, Dickinson & Co.
|
44.09% | -0.495 | 37.48% | 0.47x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.345 | 8.31% | 0.81x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.065 | -- | 3.42x |
|
MASI
Masimo Corp.
|
41.99% | 0.805 | 7.4% | 1.68x |
|
RMD
ResMed, Inc.
|
12.15% | 0.692 | 2.12% | 1.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$293.5M | $173.7M | 15.73% | 17.44% | 21.6% | $133.9M |
|
BDX
Becton, Dickinson & Co.
|
$2.8B | $881M | 3.72% | 6.6% | 14.96% | $1B |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
ISRG
Intuitive Surgical, Inc.
|
$1.7B | $759.7M | 16.35% | 16.38% | 30.33% | $735.6M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
West Pharmaceutical Services, Inc. vs. Competitors
-
Which has Higher Returns WST or BDX?
Becton, Dickinson & Co. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 8.37%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Becton, Dickinson & Co.'s return on equity of 6.6%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B -
What do Analysts Say About WST or BDX?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 26.04%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 4.33%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe West Pharmaceutical Services, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 BDXBecton, Dickinson & Co.3 9 0 -
Is WST or BDX More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.166, which suggesting that the stock is 16.617% more volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.828%.
-
Which is a Better Dividend Stock WST or BDX?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Becton, Dickinson & Co. offers a yield of 2.12% to investors and pays a quarterly dividend of $1.05 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BDX?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 40.63x while Becton, Dickinson & Co.'s PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.62x versus 2.59x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.62x 40.63x $804.3M $140M BDXBecton, Dickinson & Co.2.59x 33.68x $5.9B $493M
-
Which has Higher Returns WST or BSX?
Boston Scientific Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 14.91%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About WST or BSX?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 26.04%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.02%. Given that Boston Scientific Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Boston Scientific Corp. is more attractive than West Pharmaceutical Services, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 BSXBoston Scientific Corp.25 2 0 -
Is WST or BSX More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.166, which suggesting that the stock is 16.617% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.
-
Which is a Better Dividend Stock WST or BSX?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BSX?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Boston Scientific Corp.'s net income of $755M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 40.63x while Boston Scientific Corp.'s PE ratio is 51.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.62x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.62x 40.63x $804.3M $140M BSXBoston Scientific Corp.7.41x 51.38x $5.1B $755M
-
Which has Higher Returns WST or ISRG?
Intuitive Surgical, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 28.31%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B ISRGIntuitive Surgical, Inc.66.36% $1.95 $17B -
What do Analysts Say About WST or ISRG?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 26.04%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.77%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 ISRGIntuitive Surgical, Inc.14 11 1 -
Is WST or ISRG More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.166, which suggesting that the stock is 16.617% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock WST or ISRG?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or ISRG?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 40.63x while Intuitive Surgical, Inc.'s PE ratio is 76.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.62x versus 21.86x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.62x 40.63x $804.3M $140M ISRGIntuitive Surgical, Inc.21.86x 76.48x $2.5B $709.2M
-
Which has Higher Returns WST or MASI?
Masimo Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 14.46%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About WST or MASI?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 26.04%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 38.41%. Given that Masimo Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Masimo Corp. is more attractive than West Pharmaceutical Services, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 MASIMasimo Corp.4 3 0 -
Is WST or MASI More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.166, which suggesting that the stock is 16.617% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.
-
Which is a Better Dividend Stock WST or MASI?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or MASI?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are larger than Masimo Corp. quarterly revenues of $371.5M. West Pharmaceutical Services, Inc.'s net income of $140M is higher than Masimo Corp.'s net income of $53.7M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 40.63x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.62x versus 4.20x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.62x 40.63x $804.3M $140M MASIMasimo Corp.4.20x 116.80x $371.5M $53.7M
-
Which has Higher Returns WST or RMD?
ResMed, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 26.1%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About WST or RMD?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 26.04%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.22%. Given that West Pharmaceutical Services, Inc. has higher upside potential than ResMed, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 RMDResMed, Inc.8 7 1 -
Is WST or RMD More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.166, which suggesting that the stock is 16.617% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock WST or RMD?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. ResMed, Inc. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.60 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or RMD?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than ResMed, Inc.'s net income of $348.5M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 40.63x while ResMed, Inc.'s PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.62x versus 6.85x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.62x 40.63x $804.3M $140M RMDResMed, Inc.6.85x 25.05x $1.3B $348.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
